Nyxoah S.A. (NYXH)
- Previous Close
10.92 - Open
10.68 - Bid 5.00 x 20000
- Ask 10.77 x 100
- Day's Range
10.40 - 11.24 - 52 Week Range
4.00 - 20.00 - Volume
21,112 - Avg. Volume
59,411 - Market Cap (intraday)
318.664M - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
-- - EPS (TTM)
-1.65 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.37
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
www.nyxoah.comRecent News: NYXH
Performance Overview: NYXH
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NYXH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NYXH
Valuation Measures
Market Cap
307.22M
Enterprise Value
259.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
63.91
Price/Book (mrq)
2.91
Enterprise Value/Revenue
59.62
Enterprise Value/EBITDA
-6.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.86%
Return on Equity (ttm)
-39.58%
Revenue (ttm)
4.35M
Net Income Avi to Common (ttm)
-43.21M
Diluted EPS (ttm)
-1.65
Balance Sheet and Cash Flow
Total Cash (mrq)
57.75M
Total Debt/Equity (mrq)
12.96%
Levered Free Cash Flow (ttm)
-40.09M